Autres langues Immunome, Inc.

Actions

IMNM

US45257U1088

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
13,73 ^USD	-3,72 %		-11,30 %	+28,32 %

25/04	Immunome, Inc. nomme Sandra M. Swain au conseil d'administration	CI
15/04	IMMUNOME, INC. : Guggenheim persiste à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immunome Appoints Sandra M. Swain to Board of Directors	25/04
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	25/04
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting	08/04
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting	05/04
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets	28/03
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala	26/03
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	26/03
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25/03
Immunome to Participate in the Leerink Partners Global Biopharma Conference	07/03
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	04/03
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	01/03
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	21/02
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20/02
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20/02
Immunome Closes $230 Million Public Offering	16/02
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	16/02
Immunome Prices Stock Offering at $20 a Share	14/02
Immunome Announces Pricing of Public Offering of Common Stock	14/02
Immunome Announces Proposed Public Offering of Common Stock	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Immunome, Inc.

Actions

IMNM

US45257U1088

Autres langues

Filtres